A trial of PROstate radiotherapy in CONjunction with carbogen and nicotinamide (PROCON)

East and North Hertfordshire Hospitals NHS Trust (UK)0 个研究点目标入组 50 人开始时间: 2012年2月6日最近更新: 2022年9月26日

适应症

试验速览

暂无简介。

•1. Histological diagnosis of prostate adenocarcinoma of Gleason grade 3+3 or higher
•2. Radical radiotherapy is considered to be appropriate treatment
•3. Any of: PSA > 20ng/ml, Gleason grade > 8, T3 disease on MRI
•4. Patients must have radiographically documented measurable disease on pelvic MRI scan within 3 months of trial entry
•5. Age over 18 with no upper age limit
•6. Before patient registration, written informed consent must be given according to GCP and local regulations.
•7. Male participants
•8. Lower Age Limit 18 years

•1. Metastatic disease (including pelvic lymph node metastases) on conventional imaging including pelvic MRI scan and isotope bone scan within 3 months of trial entry
•2. PSA>50
•3. T4 disease on pelvic MRI scan within 3 months of trial entry
•4. Prior treatment for prostate cancer, either local or systemic (other than neoadjuvant androgen deprivation for a period of less than 3 months)
•5. Current active malignancy other than prostate cancer or nonmelanomatous skin cancer
•6. Previous radiotherapy to the pelvis
•7. Comorbid conditions such that the technique of external beam radiotherapy is inappropriate
•8. Contraindication to MRI (only applicable to patients that are being considered for entry into the imaging component of the study)
•9. Current treatment with an ACE inhibitor
•10. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule; those conditions should be discussed with the patient before registration in the trial

发起方

East and North Hertfordshire Hospitals NHS Trust (UK)